visual loss. Pneumatic displacement of SMH from the macular area using intravitreal injection of tissue plasminogen activator (tPA) and gas and vitrectomy with subretinal injection of tPA and intravitreal injection…
Stroke can cause car accidents. In our hospital, intravenous tissue plasminogen activator (t-PA) therapy was given to three ischemic stroke patients who had caused car accidents. Since stroke
used for ischemic stroke treatment. The worldwide used medicine for ischemic stroke is tissue plasminogen activator (t-PA). T-PA is a thrombolytic, which is used to lysate the thrombus
inadequate dialysis and HDC loss. From Jan 2009, our unit used infusions of recombinant tissue plasminogen activator (rtPA), Alteplase 0.1-0.2 mg/kg/hour over 1-2 hours for thrombolysis
deep vein thrombosis, arterial thrombosis and peripheral vascular thromboembolism. However, thrombolytic agents, such as tissue plasminogen activator, tend to dissolve both pathological thrombi and fibrin deposit at…
year-old housewife presented with ischemic cerebrovascular stroke. Intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) followed by mechanical thrombectomy under general anesthesia were…
Delayed thrombolytic treatment with recombinant tissue plasminogen activator (tPA) may exacerbate blood-brain barrier (BBB) breakdown after ischemic stroke and lead to lethal hemorrhagic transformation (HT). This study…
Background: Limiting reperfusion injury immediately after delayed tissue plasminogen activator (tPA) therapy in cases of acute ischemic stroke seems to be beneficial for extending the time window of this drug
Objective:One of the therapeutics for acute cerebral ischemia is tissue plasminogen activator (t-PA). Using t-PA after 3 hour time window increases the chances of hemorrhage, involving multiple
results of management of submacular hemorrhage (SMH) by pneumatic displacement (PD) without use of tissue plasminogen activator (tPA). Methods: This is a retrospective analysis from March 2007-February
Purpose: to evaluate the effect of Intravitreal tissue plasminogen activator (r-tPA) injection on improvement of visual acuity and decreasing the rate of complications in Branch Retinal Vein Occlusion (BRVO
acute ischemic stroke clinical trials are designed to study neuroprotectants when administered following thrombolysis; tissue plasminogen activator (tPA) is administered to patients within 3-4.5 hours of an ischemic…
systemic thrombolysis for PE patients with normal blood pressure. Treatment by human recombinant tissue plasminogen activator (rt-PA), alteplase saves lives of high-risk PE patients, i.e., those with hypotension
hypoxemia due to thrombosis of the bidirectional Glenn circulation. He received low dose tissue plasminogen activator (tPa) (0.03 mg/kg/hr) on ECLS with complete thrombolysis. tPa infusion was complicated
hospitalization are used as indicators of stroke severity and recovery. Intravenous t-PA (tissue plasminogen activator) is one of two treatments shown to have a positive impact. Stroke rehabilitation patients
recent cases. Methods: Acute ischemic stroke patients who were treated with intravenous recombinant tissue plasminogen activator administration within 4.5 hrs following onset were consecutively screened (n=112). All…
cochlear function to date with intravenous infusion of a glycoprotein analogous to recombinant tissue-type plasminogen activator (rt-PA): 3 mg dissolved in 250 mg of physiological saline given every ... compared with…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.